AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29562612 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment group (control)
Number of subjects: 67
Study 27430332 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroFIT program (lifestyle intervention) delivered over 12 weekly, 90-minute sessions combining classroom discussion with graded physical activity.
Number of subjects: 1000
Study 27430332 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroFIT program (lifestyle intervention)
Number of subjects: 1000
Study 27430332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness assessment of the EuroFIT program
Number of subjects: 1000
Study 27430332 — intervention group
Group type: EXPERIMENTAL
Intervention: Process evaluation of the EuroFIT program
Number of subjects: 1000
Study 25335331 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint massage dominant early comprehensive intervention
Number of subjects: 210
Study 25335331 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine therapy only)
Number of subjects: 210
Study 22733983 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) with Medtronic CoreValve prosthesis (CVP)
Number of subjects: 88
Study 22733983 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative abnormal conduction (first degree AV block and left bundle branch block)
Number of subjects: 88
Study 22733983 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >75 years
Number of subjects: 88
Study 22733983 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative heart rate <65 beats per minute
Number of subjects: 88
Study 22733983 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP oversizing >4 mm
Number of subjects: 88
Study 22733983 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP prosthesis >26 mm
Number of subjects: 88
Study 22733983 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 88
Study 22733983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular rate <65 beats per minute at the first post-operative day
Number of subjects: 88
Study 20447613 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% polyhexamethylene biguanide (PHMB)
Number of subjects: 145
Study 20447613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 19050308 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine, cyclophosphamide, and rituximab (FCR)
Number of subjects: 304
Study 19050308 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent chemoimmunotherapy protocols
Number of subjects: 304
Study 19050308 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmutated IgV(H)
Number of subjects: 304
Study 19050308 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutated IgV(H)
Number of subjects: 304
Study 19050308 — intervention group
Group type: EXPERIMENTAL
Intervention: IgV(H) MS
Number of subjects: 304
Study 16961684 — intervention group
Group type: EXPERIMENTAL
Intervention: Home delivery service (HDS) for essential dietary products (EDP)
Number of subjects: 62
Study 16961684 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional system)
Number of subjects: 62
Study 15615033 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile ECG device with integrated electrodes; patients record three special leads and send data via cellular phone.
Number of subjects: 0
Study 11083258 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 156
Study 11083258 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 156
Study 9157579 — intervention group
Group type: EXPERIMENTAL
Intervention: Desirudin (10, 15, or 20 mg bid)
Number of subjects: 159
Study 9157579 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU tid)
Number of subjects: 159
Study 9157579 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 159
Study 8143568 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrigid reclining infant seat (3‐h sessions, twice a day for 6‐ to 7‐week period)
Number of subjects: 20
Study 8143568 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 3519825 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation nurse support during early weeks after parturition
Number of subjects: 649
Study 3519825 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lactation nurse support)
Number of subjects: 649
Study 3519825 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation nurse support
Number of subjects: 649
Study 29209863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - One-time clinical medication review
Number of subjects: 145
Study 29209863 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - Usual care
Number of subjects: 145
Study 26802945 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive rehabilitation
Number of subjects: 39
Study 26802945 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 39
Study 23921559 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthogonal plating
Number of subjects: 67
Study 23921559 — intervention group
Group type: COMPARATOR
Intervention: Parallel plating
Number of subjects: 67
Study 21916526 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD regimen
Number of subjects: 140
Study 21916526 — intervention group
Group type: COMPARATOR
Intervention: BEACOPP and CEC regimens
Number of subjects: 140
Study 20539277 — intervention group
Group type: EXPERIMENTAL
Intervention: TT homozygous men with treated hypertension
Number of subjects: 2836
Study 20539277 — intervention group
Group type: COMPARATOR
Intervention: C allele carriers
Number of subjects: 2836
Study 18294268 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-SOD 40 mg
Number of subjects: 42
Study 18294268 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-SOD 80 mg
Number of subjects: 42
Study 16047459 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose omeprazole (200 mg/day)
Number of subjects: 105
Study 16047459 — intervention group
Group type: COMPARATOR
Intervention: Low-dose omeprazole (80 mg/day)
Number of subjects: 105
Study 16047459 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose and low-dose omeprazole
Number of subjects: 105
Study 16047459 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin level <3 g/dL
Number of subjects: 105
Study 12445227 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine‐alcohol mouthrinse (CHX‐Alc)
Number of subjects: 16
Study 12445227 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% CHX + 0.05% cetylpyridinium chloride + 0.14% zinc lactate mouthrinse (CHX‐CPC‐Zn)
Number of subjects: 16
Study 12445227 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (125 ppm F‐/125 ppm F‐) mouthrinse (AmF/SnF2Mr)
Number of subjects: 16
Study 12445227 — intervention group
Group type: EXPERIMENTAL
Intervention: Slurry of toothpaste containing amine fluoride (350 ppm F‐) and stannous fluoride (1050 ppm F‐) (AmF/SnF2Sl)
Number of subjects: 16
Study 12445227 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 16
Study 10515650 — intervention group
Group type: EXPERIMENTAL
Intervention: Active non-steroidal anti-inflammatory drug (NSAID) for 6 weeks
Number of subjects: 473
Study 10515650 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 473
Study 8536776 — intervention group
Group type: EXPERIMENTAL
Intervention: TER 5 mg once in the morning (AM)
Number of subjects: 43
Study 8536776 — intervention group
Group type: EXPERIMENTAL
Intervention: TER 5 mg once in the evening (PM)
Number of subjects: 43
Study 8536776 — intervention group
Group type: EXPERIMENTAL
Intervention: DOX 4 mg once in the morning (AM)
Number of subjects: 43
Study 8536776 — intervention group
Group type: EXPERIMENTAL
Intervention: DOX 4 mg once in the evening (PM)
Number of subjects: 43
Study 1775604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine (THA), a cholinesterase inhibitor
Number of subjects: 0
Study 7274074 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (Elipten) 250-1500 mg/d by mouth
Number of subjects: 17
Study 7274074 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide alone
Number of subjects: 17
Study 7274074 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide in combination with cytostatic drugs
Number of subjects: 17
Study 7274074 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide
Number of subjects: 17
Study 30649551 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Assessment of SpondyloArthritis international Society-RS
Number of subjects: 3877
Study 30649551 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiReumaPt-RS
Number of subjects: 3877
Study 30649551 — intervention group
Group type: COMPARATOR
Intervention: Other RSs
Number of subjects: 3877
Study 30649551 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive RS
Number of subjects: 3877
Study 28657769 — intervention group
Group type: EXPERIMENTAL
Intervention: Monurelle Biogel® vaginal gel
Number of subjects: 95
Study 28657769 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 95
Study 26312777 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional CXL (Dresden protocol)
Number of subjects: 43
Study 26312777 — intervention group
Group type: COMPARATOR
Intervention: CXL with mechanical compression (CRXL)
Number of subjects: 43
Study 23706506 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual training
Number of subjects: 16
Study 23706506 — intervention group
Group type: COMPARATOR
Intervention: Sudden training
Number of subjects: 16
Study 21345571 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult intubation (IDS >5)
Number of subjects: 650
Study 21345571 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications within 5 min of intubation
Number of subjects: 650
Study 21345571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation difficulty (IDS score)
Number of subjects: 650
Study 21345571 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult intubation
Number of subjects: 650
Study 19064978 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 439
Study 19064978 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 439
Study 17575680 — intervention group
Group type: EXPERIMENTAL
Intervention: 2HRZE3/6HE regimen (thrice-weekly direct dosing in the intensive phase and once-weekly with six doses self-administered in the continuation phase)
Number of subjects: 450
Study 17575680 — intervention group
Group type: EXPERIMENTAL
Intervention: 2HRZE3/6HE regimen
Number of subjects: 450
Study 15248627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg orally 1 h before operation and again at 6 and 12 h after the initial dose.
Number of subjects: 61
Study 15248627 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g orally at the same time intervals as ibuprofen.
Number of subjects: 61
Study 15248627 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ibuprofen 800 mg and acetaminophen 1 g.
Number of subjects: 61
Study 15248627 — intervention group
Group type: COMPARATOR
Intervention: Control group (Acetaminophen group).
Number of subjects: 61
Study 10855913 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported discharge after an acute admission
Number of subjects: 9
Study 9030833 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D receptor genotype
Number of subjects: 69
Study 8315263 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide (20 mg)
Number of subjects: 14
Study 8315263 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (80 mg)
Number of subjects: 14
Study 3548346 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma infusion
Number of subjects: 11
Study 3548346 — intervention group
Group type: COMPARATOR
Intervention: Stored plasma infusion
Number of subjects: 11
Study 3548346 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion
Number of subjects: 11
Study 3548346 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily infusion of 1,000 ml of fresh frozen plasma for 7 to 18 days
Number of subjects: 11
Study 3548346 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracentesis to reduce intraperitoneal pressure
Number of subjects: 11
Study 3548346 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of a LeVeen shunt
Number of subjects: 11
Study 31409130 — intervention group
Group type: EXPERIMENTAL
Intervention: Lachin-Foulkes adjustment to sample size and noninferiority margin
Number of subjects: 0
Study 31409130 — intervention group
Group type: EXPERIMENTAL
Intervention: Lachin-Foulkes adjustment
Number of subjects: 0
Study 31409130 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrandom nonadherence associated with a prognostic risk score
Number of subjects: 0
Study 31409130 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed sensitivity analysis
Number of subjects: 0
Study 28162769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood placental growth factor (PIGF)
Number of subjects: 190
Study 28162769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 190
Study 28162769 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operator curve analysis for PIGF
Number of subjects: 190
Study 28162769 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operator curve analysis for G-CSF
Number of subjects: 190
Study 25884885 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVI-KIDS (intervention group)
Number of subjects: 21
Study 25884885 — intervention group
Group type: COMPARATOR
Intervention: Control (control group)
Number of subjects: 21
Study 23945890 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl chloride cuff (PVC) ETT
Number of subjects: 96
Study 23945890 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane cylindrical Sealguard ETT
Number of subjects: 96
Study 23945890 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane Taperguard ETT
Number of subjects: 96
Study 21210279 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill 100-m sprint
Number of subjects: 11
Study 21210279 — intervention group
Group type: COMPARATOR
Intervention: Field 100-m sprint
Number of subjects: 11
Study 21210279 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill and field performance comparison
Number of subjects: 11
Study 21210279 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 11
Study 20008210 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin medications
Number of subjects: 1
Study 17925518 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral skills maintenance (BSM)
Number of subjects: 204
Study 17925518 — intervention group
Group type: EXPERIMENTAL
Intervention: Social facilitation maintenance (SFM)
Number of subjects: 204
Study 17925518 — intervention group
Group type: EXPERIMENTAL
Intervention: BSM and SFM together
Number of subjects: 204
Study 17925518 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204
Study 17925518 — intervention group
Group type: EXPERIMENTAL
Intervention: SFM alone
Number of subjects: 204
Study 15266759 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal sildenafil (25 mg four times daily intravaginally)
Number of subjects: 0
Study 15266759 — intervention group
Group type: COMPARATOR
Intervention: Vaginal estradiol (E2)
Number of subjects: 0
Study 11866680 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (13‐cis‐retinoic acid)
Number of subjects: 0
Study 9880129 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist cuff oscillometric blood pressure device
Number of subjects: 100
Study 9880129 — intervention group
Group type: COMPARATOR
Intervention: Mercury manometer
Number of subjects: 100
Study 7728133 — intervention group
Group type: EXPERIMENTAL
Intervention: FTBI/VP-16 regimen
Number of subjects: 0
Study 7728133 — intervention group
Group type: EXPERIMENTAL
Intervention: FTBI/VP-16 regimen with added CY 60 mg/kg
Number of subjects: 0
Study 2706191 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral activated charcoal
Number of subjects: 7
Study 29040021 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Sigmoidoscopy (FS)
Number of subjects: 1984
Study 29040021 — intervention group
Group type: EXPERIMENTAL
Intervention: CT Colonography (CTC)
Number of subjects: 1984
Study 29040021 — intervention group
Group type: COMPARATOR
Intervention: CT Colonography (CTC) Nonattendees
Number of subjects: 1984
Study 28257942 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal defaults
Number of subjects: 0
Study 28257942 — intervention group
Group type: COMPARATOR
Intervention: Suboptimal defaults
Number of subjects: 0
Study 28257942 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent empowerment priming
Number of subjects: 0
Study 28257942 — intervention group
Group type: COMPARATOR
Intervention: Neutral priming
Number of subjects: 0
Study 26650152 — intervention group
Group type: COMPARATOR
Intervention: Standard-care group (permethrin to affected persons and contacts)
Number of subjects: 2051
Study 26650152 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin group (mass administration of permethrin)
Number of subjects: 2051
Study 26650152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin group (mass administration of ivermectin)
Number of subjects: 2051
Study 23499145 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior thoracic manipulation of T1-4
Number of subjects: 36
Study 23499145 — intervention group
Group type: COMPARATOR
Intervention: Activator-based placebo manipulation
Number of subjects: 36
Study 23499145 — intervention group
Group type: COMPARATOR
Intervention: No T-spine contact control
Number of subjects: 36
Study 22468309 — intervention group
Group type: EXPERIMENTAL
Intervention: HanFangJiaSu
Number of subjects: 71
Study 22468309 — intervention group
Group type: COMPARATOR
Intervention: XiFeiNing
Number of subjects: 71
Study 19938938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation intervention for smokeless tobacco users
Number of subjects: 337
Study 19938938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation intervention for smokers
Number of subjects: 337
Study 19938938 — intervention group
Group type: COMPARATOR
Intervention: Control condition for smokeless tobacco users
Number of subjects: 337
Study 19938938 — intervention group
Group type: COMPARATOR
Intervention: Control condition for smokers
Number of subjects: 337
Study 16753403 — intervention group
Group type: EXPERIMENTAL
Intervention: PlasmaKinetic prostate vaporization
Number of subjects: 160
Study 16753403 — intervention group
Group type: COMPARATOR
Intervention: Transurethral prostate resection
Number of subjects: 160
Study 15003080 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine + Clonazepam (1.0 to 2.0 mg/day, divided b.i.d.)
Number of subjects: 28
Study 15003080 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine + Placebo
Number of subjects: 28
Study 15003080 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine + Clonazepam
Number of subjects: 28
Study 11762415 — intervention group
Group type: EXPERIMENTAL
Intervention: Zevalin (ibritumomab tiuxetan) at a dose of 0.4 mCi/kg for patients with platelet counts > 150,000 and < 25% bone marrow involvement; 0.3 mCi/kg for patients with platelet counts between 100,000-149,000.
Number of subjects: 0
Study 11762415 — intervention group
Group type: EXPERIMENTAL
Intervention: Zevalin (ibritumomab tiuxetan)
Number of subjects: 0
Study 11762415 — intervention group
Group type: COMPARATOR
Intervention: Rituximab at a standard dose of 375 mg/m2 weekly for four weeks (control group).
Number of subjects: 0
Study 11762415 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrandomized trial of Zevalin in patients refractory to rituximab.
Number of subjects: 0
Study 11762415 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II study of reduced dose of Zevalin in patients with mild thrombocytopenia.
Number of subjects: 0
Study 9327113 — intervention group
Group type: EXPERIMENTAL
Intervention: Marezine (50 mg)
Number of subjects: 23
Study 9327113 — intervention group
Group type: COMPARATOR
Intervention: Dramamine (50 mg)
Number of subjects: 23
Study 7878561 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion at total lung capacity (TLC)
Number of subjects: 12
Study 7878561 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion at residual volume (RV)
Number of subjects: 12
Study 7878561 — intervention group
Group type: COMPARATOR
Intervention: Occlusion at RV
Number of subjects: 12
Study 7878561 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion at TLC
Number of subjects: 12
Study 2564563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg daily
Number of subjects: 37
Study 2564563 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole 200 mg daily
Number of subjects: 37
Study 5440241 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine multiple blood tests
Number of subjects: 296
Study 31690281 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal lifestyle intervention using a web-based tool, duration: 12 months
Number of subjects: 244
Study 31690281 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal lifestyle intervention using a web-based tool
Number of subjects: 244
Study 31690281 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (control group)
Number of subjects: 244
Study 28500463 — intervention group
Group type: EXPERIMENTAL
Intervention: NIO™
Number of subjects: 87
Study 28500463 — intervention group
Group type: COMPARATOR
Intervention: BIG®
Number of subjects: 87
Study 28500463 — intervention group
Group type: COMPARATOR
Intervention: EZ‐IO®
Number of subjects: 87
Study 28500463 — intervention group
Group type: COMPARATOR
Intervention: Jamshidi
Number of subjects: 87
Study 25409592 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (160 mg/day)
Number of subjects: 17
Study 25409592 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 17
Study 25409592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 25409592 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 17
Study 23306100 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT plus docetaxel
Number of subjects: 385
Study 23306100 — intervention group
Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 385